Project Grant R01CA299261
Award Date
4/11/25
Completion Date
3/31/30
Dollars Obligated
$425K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $3,787,956.00 to New York University School of Medicine to conduct research aimed at improving the understanding and treatment of small cell lung cancer (SCLC). The key research objectives are: Investigating how the gene SLFN11 impacts chemotherapy responsiveness in different SCLC subtypes. Studying how replication stress response pathways and modulators regulate...
This $670,358 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of B cells in mediating response to neoadjuvant immune-based therapy for patients with resectable non-small cell lung cancer (NSCLC). The key objectives are to: 1) Determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in NSCLC treated with...
This $530,786 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Leland Stanford Junior University (Stanford University) to investigate cell state-specific vulnerabilities in small cell lung cancer (SCLC) that can be targeted for therapeutic benefit. The key focus is on understanding how cysteine metabolism regulates distinct cell death pathways in neuroendocrine versus non-neuroendocrine SCLC cell states. The...
This $680,507 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to elucidate mechanisms of cancer persister cell resistance and identify druggable targets to eliminate persistence in KRAS-mutant non-small cell lung cancer. The 5-year project at the University of California, San Francisco will: 1) Illuminate signals that promote persistence in physiologically relevant contexts; 2) Identify and validate targets that inhibit persistence;...
This $230,010 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by the University of Chicago to investigate the drivers of metastasis in small cell lung cancer (SCLC). The researchers aim to leverage human pluripotent stem cell-derived lung cancer models, patient samples, and advanced technologies like single-cell sequencing to uncover the cellular and molecular mechanisms underlying SCLC's aggressive metastatic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $449,196 in funding to The University of Texas Southwestern Medical Center (UT Southwestern) over a 5-year period from April 1, 2025 to March 31, 2030. The grant supports research to investigate the mechanisms of resistance to tyrosine kinase inhibitor (TKI) therapies in non-small cell lung cancer (NSCLC) patients. Specifically, the project focuses on understanding how TKIs...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $216,972 to Temple University to conduct research focused on understanding and targeting vulnerabilities related to cell cycle regulation and replication stress in small cell lung cancer (SCLC). The key objectives of the research are: 1) determining the mechanistic relationship between low levels of the nuclear structural protein LMNA and increased replication stress in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,408,844.00 to the Sloan-Kettering Institute for Cancer Research to characterize the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate. The key objectives are to utilize a DLL3-targeted radiolabeled monoclonal antibody for non-invasive diagnosis using PET imaging (89Zr-DFO-SC16.56 AB) and as an image-based therapy...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to evaluate the role of metabolism in persister cell survival within mammalian cell populations. The total funding amount is $398,282 and the award date is April 18, 2025, with a project period ending on March 31, 2030. The key products and services to be delivered under this grant include: Verifying the hypothesis that persister cells have a transient metabolic state characterized by...